Log in to save to my catalogue

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lun...

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lun...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_286176aadbbc411dbfd32550becc33c5

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

About this item

Full title

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2020-09, Vol.11 (1), p.4607-14, Article 4607

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Drug tolerance is the basis for acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) including osimertinib, through mechanisms that still remain unclear. Here, we show that while AXL-low expressing
EGFR
mutated lung cancer (
EGFR
mut-LC) cells are more sensitive to osimertinib than AXL-high expr...

Alternative Titles

Full title

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_286176aadbbc411dbfd32550becc33c5

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_286176aadbbc411dbfd32550becc33c5

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-020-18442-4

How to access this item